Gene Location [1]
MAP kinase signaling
Variant Type
Substitution - Missense
Affected Exon Number
SIFT Prediction [3]
ClinVar Prediction [3]

KRAS G13D is present in 1.07% of AACR GENIE cases, with colon adenocarcinoma, colorectal adenocarcinoma, lung adenocarcinoma, rectal adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence [4].

Top Disease Cases with KRAS G13D

Biomarker-Directed Therapies

Significance of KRAS G13D in Diseases

Non-Small Cell Lung Carcinoma +

Colorectal Carcinoma +

Malignant Solid Tumor +

Squamous Cell Lung Carcinoma +

Acute Myeloid Leukemia +

Colorectal Adenocarcinoma +

Pancreatic Carcinoma +

Rectal Carcinoma +

Malignant Colorectal Neoplasm +

Gastric Carcinoma +

Lung Adenocarcinoma +

Pancreatic Adenocarcinoma +

Ovarian Carcinoma +

Breast Carcinoma +

Anal Canal Squamous Cell Carcinoma +

Chordoma +

Glioblastoma +

Glioma +

Head And Neck Squamous Cell Carcinoma +

Hepatocellular Carcinoma +

Multiple Myeloma +

Myelodysplastic Syndromes +

Pancreatic Ductal Adenocarcinoma +

Small Cell Lung Carcinoma +

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +

Uveal Melanoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.